Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder.
|Title||Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder.|
|Publication Type||Journal Article|
|Year of Publication||2008|
|Authors||Findling, RL, Childress AC, Krishnan S, McGough JJ|
|Date Published||2008 Jul|
|Keywords||Administration, Oral, Appetite, Attention Deficit Disorder with Hyperactivity, Child, Dextroamphetamine, Diagnostic and Statistical Manual of Mental Disorders, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Headache, Humans, Male, Psychiatric Status Rating Scales, Sleep Initiation and Maintenance Disorders, Time Factors, Treatment Outcome, Weight Loss|
Lisdexamfetamine dimesylate (LDX), a prodrug stimulant, is indicated for attention-deficit/hyperactivity disorder (ADHD) in children 6-12 years of age and in adults. In short-term studies, once-daily LDX provided efficacy throughout the day. This study presented here was conducted to assess the long-term safety, tolerability, and effectiveness of LDX in 6- to 12-year-olds with ADHD.
|Alternate Journal||CNS Spectr|